Related Experiment Videos
[Application of hammerhead ribozyme targeting telomerase molecule for cancer therapy]
Y Yokoyama1, Y Takahashi, A Shinohara
1Department of Obstetrics and Gynecology, Gifu University School of Medicine.
Abstract:
Because telomerase is expressed in most cancer cells, but not in most normal somatic cells, telomerase is a promising target molecule of human cancer therapy. To reduce telomerase activity in cancer cells, a hammerhead ribozyme is a choice. The RNA component of telomerase (hTR) is an essential molecule for telomerase, therefore hammerhead ribozyme against it can directly interfere with the telomerase activity. The expression level of hEST2, a catalytic subunit of telomerase correlates well to telomerase activity. Hammerhead ribozyme against hEST2 mRNA, therefore, will reduce telomerase activity by breaking its transcript down. Although hammerhead ribozyme can be designed to target any particular three-base sequences; it is still difficult to predict its efficiency in vivo. Application of hammerhead ribozyme targeting hTR is discussed.
Insights
Hammerhead ribozymes targeting human telomerase RNA (hTR) or its catalytic subunit (hEST2) show promise for cancer therapy by reducing telomerase activity. Further research is needed to predict in vivo efficiency for therapeutic applications.
Area of Science:
- Molecular Biology
- Biochemistry
- Cancer Research
Context:
- Telomerase is highly expressed in most cancer cells but not normal cells, making it a prime therapeutic target.
- Hammerhead ribozymes offer a potential strategy to inhibit telomerase activity by degrading essential RNA components.
- The catalytic subunit of telomerase, hEST2, and its mRNA are key targets for ribozyme-mediated inhibition.
Purpose:
- To explore the potential of hammerhead ribozymes as a therapeutic strategy against cancer by targeting telomerase.
- To investigate the direct interference with telomerase activity by targeting the RNA component of telomerase (hTR).
- To assess the feasibility of reducing telomerase activity by degrading hEST2 mRNA using hammerhead ribozymes.
Summary:
- Hammerhead ribozymes can be designed to target specific sequences in hTR or hEST2 mRNA.
- Degradation of hTR or hEST2 mRNA by ribozymes directly reduces telomerase activity.
- While effective in vitro, predicting the in vivo efficiency of hammerhead ribozymes remains a challenge.
Impact:
- Successful application of hammerhead ribozymes could lead to novel cancer therapies with reduced side effects.
- This approach offers a targeted mechanism to inhibit cancer cell proliferation by disrupting telomerase function.
- Further development could overcome challenges in predicting in vivo efficacy, paving the way for clinical translation.